International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

"A Comprehensive Review on Pilot Plant Scale up And Platform Technology"

Nikhil Kumar[1], Abhishek Meghwal[2], Rumita Kumawat[3*], Dr. Raghvendra Singh Bhadauria[4]

1. *Student B. Pharm VIII Sem, Sunrise College of Pharmacy, Umarda, Udaipur (Rajasthan)*
2. *Student B. Pharm VIII Sem, Sunrise College of Pharmacy, Umarda, Udaipur (Rajasthan)*
3. *Assistant Professor, Sunrise College of Pharmacy, Umarda, Udaipur (Rajasthan)*
4. *Principal, Sunrise College of Pharmacy, Umarda, Udaipur (Rajasthan)*

Date of Submission: 28-05-2025 Date of Acceptance: 08-06-2025

ABSTRACT
The pharmaceutical business uses pilot plant scale-up strategies to create reliable manufacturing procedures and turn lab-scale formulas into commercial products. The place called Pilot is where the five elements Material, Man, Method, and Machine are combined to manufacture things. A tiny, basic lab scale formula will be tested on a replica of the intended plant in the pilot plant before spending a significant amount of money on a production unit. Scaling up a pilot plant provides information on formula examination, reviewing the range of pertinent processing equipment, understanding raw material specifications, production rate, and physical space requirements. It can hold accurate documentation and reports for analysis in support of the GMP procedure. This review research discusses the parameters such as granulation feed rate,compression parameters, temperature and rate of drying will have acritical role in development of any solid dosage form. The primary goal of a pilot plant is to identify errors on a small scale and generate revenue on a large scale.
Keywords- pilot-plant, solid dosage form, SUPAC, Scale-up, GMP.

I. INTRODUCTION

PLANT:

In industrial pharmacy, a plant refers to the physical infrastructure where the manufacturing, processing, and packaging of pharmaceutical products occur. These facilities must adhere to strict regulatory requirements, such as Good Manufacturing Practices (GMP), to ensure the safe, consistent production of high-quality drug products[1].

Structure of a Pharmaceutical Plant[1,2]

A pharmaceutical plant consists of the following key components:

- **Manufacturing Areas:** Zones for producing bulk drug substances and final dosage forms (e.g., tablets, capsules).
- **Processing Equipment:** Includes mixers, granulators, fluid bed dryers, tablet presses, coaters, and packaging lines.
- **Quality Control Laboratories:** Equipped to test raw materials, in-process samples, and final products to ensure compliance with regulatory standards.
- **Storage Facilities:** For raw materials, excipients, packaging materials, and finished goods.
- **Clean Rooms:** Controlled environments to minimize microbial and particulate contamination.
- **Utilities and Infrastructure:** HVAC systems, purified water units, waste management, and compressed air systems that support production.

Pilot Plant:

A pilot plant acts as an intermediate stage between laboratory-scale research and commercial production. It enables development, testing, and validation of processes before full-scale implementation[3].

Key Features of a Pilot Plant[1,3,9]:

- Process Development: Allows optimization of drug formulation and processing techniques.
- Process Validation: Confirms that the process is reproducible and consistent.
- Small-Scale Production: Produces sufficient product for clinical trials or market testing.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

- Technology Transfer: Transfers knowledge and process know-how from R&D to manufacturing.

Scale-Up:
Scale-up refers to increasing batch size or production capacity while ensuring that product quality, efficacy, and safety remain unchanged. It transforms laboratory success into market-ready manufacturing[3].

Key Aspects of Scale-Up:
1. Process Optimization: Fine-tuning processing parameters (e.g., mixing time, temperature) for larger-scale equipment.
2. Equipment Adaptation: Selecting larger equipment capable of mimicking lab-scale results.
3. Quality Control: Maintaining Critical Quality Attributes (CQAs) like uniformity, purity, and stability.
4. Process Validation: Demonstrating consistent batch performance through rigorous testing.
5. Cost and Efficiency: Ensuring resource optimization and economic viability for commercial scale.

Objectives of Pilot Plant Studies[1,3,4,6]

The primary goal of pilot plant studies is to bridge laboratory research and full-scale production, ensuring that the developed process is reliable, reproducible, and cost-effective.

Key Objectives:
1. Process Development and Optimization: Testing and improving processing parameters for scalability.
2. Feasibility Assessment: Evaluating the possibility of scaling lab results to production scale.
3. Validation of Manufacturing Processes: Ensuring consistency in quality across larger batches.
4. Technology Transfer: Facilitating smooth communication between R&D and manufacturing teams.
5. Regulatory Compliance: Generating data needed for submissions to agencies like the FDA and EMA.
6. Cost Evaluation: Assessing the cost of materials and production at a commercial level.
7. Risk Identification: Recognizing and mitigating production risks before full-scale rollout.

Significance of Pilot Plant Studies[4,25]
Pilot plants are critical in transforming lab-scale research into viable production processes.
Importance:
1. Risk Mitigation: Identifies issues before large-scale investment.
2. Product Quality Assurance: Maintains standards during upscaling.
3. Seamless Scale-Up: Ensures smooth transition from lab to commercial scale.
4. Cost-Effectiveness: Optimizes resource use and reduces waste.
5. Regulatory Approval: Supports data generation for approvals.
6. Fosters Innovation: Provides a testing ground for new methods and technologies.

Need for Pilot Plant Studies[2, 4,15,36]

Pilot plant studies are essential for ensuring that a developed drug formulation is safe, effective, and commercially feasible when scaled up.

Why It's Needed:
1. Validates Lab Processes: Ensures lab results are scalable.
2. Problem Solving: Identifies equipment or process issues early.
3. Improves Efficiency: Optimizes process parameters before scale-up.
4. Cost Estimation: Projects expenses of full-scale production.
5. Ensures Product Quality: Maintains high standards during manufacturing.
6. Compliance and Safety: Meets environmental, health, and regulatory requirements.

S. No.	Uses	Details
1.	**Process Development**	Testing new technologies and optimizing formulations.
2.	**Scale-Up Studies**	Transition from lab to industrial scale; identify scale-up challenges.
3.	**Cost Analysis**	Conducting feasibility studies and cost evaluation.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

S. No.	Uses	Details
4.	**Product Testing**	Producing small trial batches for quality testing and clinical evaluation.
5.	**Regulatory Compliance**	Generating data for GMP and regulatory submissions.
6.	**R&D Collaboration**	Fostering partnerships between academia and industry for innovation.
7.	**Sustainability Initiatives**	Developing eco-friendly, low-waste, energy-efficient processes.
8.	**Training & Skill Development**	Providing practical experience for operators and staff.
9.	**Customized Production**	Exploring personalized medicine and patient-specific formulations.
10.	**Advanced Technology Integration**	Implementing automation and novel technologies to enhance productivity.

Table No. 1: Uses of Pilot Plant in Industrial Pharmacy

STEPS INVOLVED IN PILOT PLANT STUDIES & SCALE-UP

The process of scale-up serves as a critical bridge between laboratory-scale research and full-scale industrial manufacturing. Pilot plant studies play a fundamental role in ensuring that the developed pharmaceutical process is **scalable, economically viable**, and **regulatory compliant**, while also retaining product quality, safety, and efficacy. The scale-up process consists of a series of well-defined steps that contribute to successful commercialization[5].

Process Understanding[2, 4, 5, 34]

Objective:

To develop a deep understanding of the chemical, physical, and mechanical aspects of the process to be scaled up.

Key Activities:

- Conduct small-scale laboratory experiments to gather baseline data.
- Analyze**reaction kinetics**, **heat and mass transfer** rates, **material flow properties**, and **process dynamics**.
- Identify **Critical Process Parameters (CPPs)** and **Critical Quality Attributes (CQAs)** to establish control points essential for product quality.
- Determine sensitivity of the process to changes in temperature, pressure, pH, or ingredient concentration.

Outcome:

Comprehensive understanding of the process that helps anticipate potential challenges during scale-up and provides foundational knowledge for design and optimization stages.

Pilot Plant Trials[4,5]

Objective:

To evaluate the feasibility, reproducibility, and safety of the process under pilot-scale conditions, which simulate industrial-scale production.

Key Activities:

- Operate the process in a pilot plant using scaled-down versions of industrial equipment.
- Monitor parameters like **batch yield**, **cycle time**, **process stability**, and **operational efficiency**.
- Validate safety protocols and evaluate potential risks such as **equipment failure**, **chemical hazards**, or **cross-contamination**.
- Identify inconsistencies between lab-scale and pilot-scale performance.

Outcome:

Pilot trial data serves as the basis for refining process parameters, equipment design, and safety measures. It also generates a **feasibility report** and supports go/no-go decisions for scale-up.

Equipment Design and Selection[3, 5]

Objective:

To design or select industrial equipment that meets process requirements and ensures efficient, reproducible production.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

Key Activities:

- Determine appropriate **reactors**, **mixers**, **dryers**, **granulators**, and other processing equipment.
- Scale equipment capacity based on anticipated batch size while ensuring mechanical and thermal efficiency.
- Select **materials of construction** (e.g., stainless steel, glass-lined steel) considering process chemistry, corrosion, and cleaning requirements.
- Design for **ease of maintenance**, **automation**, and **compliance with GMP**.

Outcome:

Tailor-made, scalable equipment designed to match the exact needs of the process while ensuring safety, efficiency, and quality.

Process Optimization[4, 5]

Objective:

To improve process performance and reduce variability, waste, and costs without compromising product quality.

Key Activities:

- Fine-tune process variables such as **temperature**, **agitation speed**, **residence time**, and **pressure**.
- Implement **Design of Experiments (DoE)** and **response surface methodology (RSM)** for multi-variable optimization.
- Optimize **raw material usage**, **energy consumption**, and **cycle times** to improve process economics.
- Establish **Standard Operating Procedures (SOPs)** and **batch manufacturing records (BMRs)** for reproducibility.

Outcome:

An optimized, high-yield, and resource-efficient process that is ready for validation and commercial production.

Addressing Scale-Up Challenges[4, 5, 20, 21]

Objective:

To proactively identify and mitigate challenges associated with moving from pilot to commercial scale.

Common Challenges:

- **Temperature Control**: Larger equipment may lead to uneven heat distribution or poor thermal conductivity.
- **Mixing Efficiency**: Homogeneity becomes harder to achieve at larger volumes due to varying fluid dynamics.
- **Energy Requirements**: Increased scale may raise energy demands, requiring specialized infrastructure.
- **Reproducibility**: Ensuring consistent quality and performance across different batches and scales.

Solutions:

- Implement **automated monitoring and control systems** (e.g., PAT tools, SCADA systems).
- Conduct detailed **risk assessments** (FMEA, HAZOP).
- Optimize equipment design to improve **mixing**, **cooling**, and **material handling**.
- Use simulation and modeling software to predict and troubleshoot scale-up behavior.

Outcome:

A well-controlled and predictable process that maintains product integrity at full production scale.

Regulatory Considerations[3, 5, 16, 17, 28]

Objective:

To ensure that the scaled-up process complies with all **regulatory** and **quality assurance standards** set by governing agencies such as the **FDA**, **EMA**, or local authorities.

Key Activities:

- Prepare complete **documentation** for process validation, including batch records, cleaning protocols, and quality control measures.
- Conduct **process validation studies** (IQ/OQ/PQ) to demonstrate consistent performance of equipment and processes.
- Ensure adherence to **Good Manufacturing Practices (GMP)**, **ICH guidelines**, and relevant pharmacopoeial standards.
- Perform **risk management**, **change control**, and **quality audits** to validate and maintain compliance.

Outcome:

A regulatory-compliant and validated process that is qualified for large-scale production and supports product registration and commercialization.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

Step	Objective	Key Outcomes
1. Process Understanding	Identify critical parameters and behavior	Informed decisions for optimization and design
2. Pilot Plant Trials	Simulate industrial scale and identify issues	Feasibility data and refinement of protocols
3. Equipment Design	Select equipment compatible with process needs	Scalable, efficient production setup
4. Process Optimization	Improve efficiency and reduce costs	Optimized operating parameters and resource use
5. Scale-Up Challenges	Address mechanical and process-related difficulties	Solutions for reproducibility and operational issues
6. Regulatory Considerations	Ensure compliance and product safety	Validated, audit-ready production process

Table No.2: Steps involved in pilot plant & scale up in industrial Pharmacy



Figure No. 01 Flow Diagram for Scale-Up Process

GENERAL CONSIDERATIONS FOR PILOT PLANT

The success of a pilot plant lies in a comprehensive understanding of design, operation, and compliance. Each aspect is carefully tailored to replicate industrial production while remaining flexible for experimentation and scale-up[6, 7, 8, 16, 17].

Facility Design and Layout

a. Scalable Design:

- The pilot plant layout should closely resemble a full-scale manufacturing facility.
- Integrates key operational areas: processing zones, QC labs, raw material storage, and finished goods areas.

b. Hygienic Environment:

- Use non-porous, easy-to-clean materials for floors and walls.
- Install HEPA filters and controlled airflow to prevent contamination.

c. Safety Measures:

- Use fire-retardant construction, fire alarms, and emergency exits.
- Segregate chemical handling zones to reduce risks.

d. Utility and Accessibility:

- Utilities like steam, water, and compressed air should be strategically placed for easy access.
- Ensure enough space for smooth movement of personnel and material.

Equipment Selection and Adaptability

a. Scalability:

- Select equipment such as reactors, dryers, and granulators that reflect proportional scaling principles.
- Equipment must be capable of mimicking full-scale process dynamics.

b. Material of Construction:

- Stainless steel for pharmaceuticals.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

- Glass-lined or polymer-coated vessels for corrosive chemicals.

c. Maintenance and Standardization:
- Equipment must allow easy dismantling and reassembly.
- Use components with readily available spare parts.

d. Automation and Control:
- Employ PLC and DCS systems for control and automation.
- Enable real-time parameter monitoring and data logging.

Environmental and Safety Compliance
a. Regulatory Adherence:
- Design in line with GMP, FDA, ISO 14644 standards.
- Maintain complete validation documentation.

b. Waste and Emissions Control:
- Install scrubbers, condensers, and solid waste treatment units.
- Prevent leakage and emissions from hazardous zones.

c. On-Site Safety Infrastructure:
- Emergency showers, eye-wash stations, fire extinguishers must be available.
- Provide PPE and ensure proper usage through regular training.

Utility and Resource Management
a. Energy Efficiency:
- Integrate energy-saving devices like VFDs.
- Utilize waste heat recovery systems to improve overall energy utilization.

b. Raw Material Management:
- Implement inventory systems to track usage and ensure batch traceability.
- Store materials in controlled environments to maintain integrity.

c. Water Management:
- Incorporate water purification and recycling systems.
- Treat wastewater before disposal or reuse.

Flexibility for Process Development
- Use multipurpose, modular equipment suitable for batch, semi-continuous, or continuous processing.
- Ensure easy interchange of filters, nozzles, and instrumentation.
- Enable testing across a range of parameters without major retrofitting.

Data Collection and Documentation
a. Real-Time Monitoring:
- Install sensors for parameters such as pH, viscosity, flow, and temperature.
- Use software for real-time data acquisition and archiving.

b. Documentation:
- Maintain SOPs, batch logs, deviation reports, and training records.
- Preserve historical data for troubleshooting and audits.

c. Data Analysis:
- Evaluate collected data to forecast scale-up issues.
- Use trends and analytics to fine-tune operating conditions.

Cost Considerations
a. ROI Assessment:
- Evaluate each investment (equipment, utilities) against its projected ROI.
- Avoid unnecessary overengineering.

b. Operational Cost Reduction:
- Optimize energy and water use.
- Apply predictive maintenance to prevent equipment failure.

c. Budget for Flexibility:
- Account for unforeseen process changes, part replacement, or upgrades.

Training and Personnel
a. Skilled Workforce:
- Employ engineers and technicians trained in scale-up and validation.
- Build a multidisciplinary team (QA/QC, process engineering, regulatory experts).

b. Continuous Learning:
- Conduct training sessions and mock drills.
- Encourage certification and GMP workshops.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

GMP CONSIDERATIONS[9, 10, 11, 12, 13]

Good Manufacturing Practices (GMP) is essential to ensure product safety, consistency, and compliance.

1. Quality Management System (QMS)
- Develop clear SOPs and policies aligned with global GMP standards.
- Ensure robust documentation for traceability.

2. Personnel and Training
- Train staff regularly on SOPs, safety, hygiene, and quality protocols.
- Maintain training logs and assess skill competencies.

3. Facility and Equipment
- Prevent cross-contamination through design.
- Regular calibration and maintenance of equipment.
- Control temperature, humidity, and air quality.

4. Materials Management
- Procure validated raw materials with CoA.
- Use barcode/RFID-based inventory systems.
- Ensure FIFO and avoid expired stock.

5. Manufacturing Processes
- Validate and monitor every process.
- Keep comprehensive batch production records.
- Monitor CPPs and CQAs throughout.

6. Packaging and Labeling
- Use tamper-evident, compliant packaging.
- Accurately label each batch with expiration, dosage, and contents.

7. Quality Control and Testing
- Conduct in-process, final, and stability testing.
- Perform routine sampling and inspections.

8. Auditing and Inspection
- Conduct regular internal and mock audits.
- Be inspection-ready for regulatory bodies like FDA, EMA, CDSCO.

9. Product Recall and Complaints
- Set up recall protocols.
- Track and resolve complaints efficiently.

10. Continuous Improvement
- Use root cause analysis for every deviation.
- Implement CAPA systems.
- Embrace innovation and regulatory updates.



Figure No. 02General Considerations During Pilot Plant Scale-up.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

ADVANTAGES OF PILOT PLANT[1, 2, 14, 15]

1. **Risk Mitigation:** Identifies issues early, reducing failure in commercial production.
2. **Cost Efficiency:** Accurate cost estimation improves financial planning.
3. **Process Optimization:** Enhances efficiency, reduces material loss.
4. **Scale-Up Validation:** Ensures lab processes translate to industrial settings.
5. **Quality Assurance:** Verifies consistency and compliance before full-scale launch.
6. **Innovation Testing:** Trial of new technologies without production risk.
7. **Regulatory Readiness:** Validates protocols under regulatory frameworks.
8. **Training Opportunities:** Hands-on experience for operators and engineers.
9. **Flexibility:** Easy testing of different formulations or equipment.
10. **Sustainable Development:** Enables low-waste, energy-saving strategies.
11. **Market Readiness:** Rapid testing helps meet market demand swiftly.
12. **Collaboration:** Bridges academia and industry for R&D progress.

DISADVANTAGES OF PILOT PLANT[1, 2, 14, 15]

1. **High Capital Investment:** Expensive to establish and equip.
2. **Time-Intensive:** Delays product launch due to setup and trials.
3. **Resource-Heavy:** Requires dedicated staff, infrastructure, and expertise.
4. **Limited Representation:** May not mirror full-scale challenges precisely.
5. **Scale-Up Issues:** Successful pilot performance doesn't guarantee industrial success.
6. **Inaccurate Predictions:** Results may not extrapolate well to large volumes.
7. **Complex Management:** Involves cross-functional coordination.
8. **Obsolescence Risk:** Rapid tech changes may outdate the system.
9. **Regulatory Challenges:** Navigating compliance is demanding.
10. **Market Risk:** Pilot-developed products may not succeed commercially.
11. **Narrow Testing Scope:** Might overlook full-scale production variables.

Pilot Scale-Up for Solid Dosage Forms:[2,4,16]

Solid dosage forms, including tablets, capsules, powders, granules, lozenges, and suppositories, dominate the pharmaceutical market due to their stability, precise dosing, and patient convenience. Pilot scale-up is a pivotal phase in pharmaceutical development, transitioning lab-scale formulations to intermediate-scale production to validate processes before full-scale manufacturing. This step ensures product quality, reproducibility, and compliance with Good Manufacturing Practices (GMP) while identifying potential issues in process parameters, equipment, or material behavior.

Objectives of Pilot Scale-Up:

- Validate process parameters for consistent quality.
- Optimize critical process steps (e.g., blending, compression).
- Establish guidelines for raw materials and equipment.
- Ensure regulatory compliance (e.g., FDA, EMA standards).

Challenges: Scaling up introduces variables such as altered mixing dynamics, material flow issues, or equipment variability. For example, a lab-scale blender may achieve uniformity in minutes, but a larger pilot-scale blender may require extended mixing due to differences in shear forces. This document outlines key considerations, unit operations, and best practices for successful pilot scale-up, integrating tables and figures to illustrate critical concepts.

Understanding Solid Dosage Forms:[3,5,17,18]

Solid dosage forms deliver active pharmaceutical ingredients (APIs) with excipients in forms like tablets, capsules, or granules. Their advantages include high precision, stability, and ease of handling, but scaling up these formulations requires addressing material and process challenges.

Key Solid Dosage Forms:

- **Tablets:** Compressed solids, often coated for stability or release control.
- **Capsules:**Gelatin shells filled with powders or granules.
- **Powders/Granules:** Used directly or as intermediates.
- **Lozenges/Suppositories:** For localized or systemic effects.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

Scale-Up Challenges:

- **Material Flow:** Poor flowability can cause segregation.
- **Blend Uniformity:** Inconsistent API distribution affects efficacy.
- **Compression Issues:** Variations in tablet weight or hardness.
- **Particle Size:** Impacts dissolution and uniformity.

Property	Impact on Scale-up	Mitigation Strategy
Flowability	Poor flow leads to Segregation	Use glidants, Optimize particle size
Particle size	Affects dissolution, Compressibility	Mill or screen granules
Density	Influences die fill, capsule filling	Adjust formulation, use roller Compaction
Hygroscopicity	Moisture uptake affects Stability	Control humidity, use moisture barriers

Table No.3: Critical Material Properties

Pilot Plant Design and Layout:[6,12,18,19]

A pilot plant is a small-scale production system designed to simulate commercial manufacturing conditions while allowing flexibility for process optimization. The design of a pilot plant for solid dosage forms must incorporate features to facilitate maintenance, cleanliness, and GMP compliance.

key Design:

- **Location:**Prefebrably on the ground floor to expedite material delivery and shipment.
- **Space Requirements:** Separate areas for administration, physical testing, equipment, and storage.
- **Equipment:** Portable, intermediate-scale machines that mimic production equipment (e.g., high-shear mixers, fluid bed dryers, tablet presses).
- **Environmental Controls:** Temperature (25°C ± 5°C), humidity (55% ± 10% RH), and pressure differentials (e.g., 10–20 Pascal in processing areas) to prevent contamination.

- **Layout Stages for Tablet Production:**

1.Material handling and weighing.
2.Dry blending or granulation.
3.Drying and particle size reduction.
4.Blending and lubrication.
5.Compression or encapsulation.
6.Coating (if applicable).

- **Personnel Requirements:** Staff with theoretical knowledge of pharmaceutics and practical experience in solid dosage manufacturing are essential. Training programs should cover equipment operation, GMP protocols, and troubleshooting.

A well-designed pilot plant minimizes scale-up risks by providing a controlled environment to test and refine processes, ensuring a smooth transition to commercial production.



Figure No. 03 Pilot Plant Layout

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

Material Handling in Pilot Scale-Up:[15,19,20]

Material handling ensures accurate and efficient transfer of powders and granules, which behave differently at larger scales compared to lab settings.

Key Considerations:

- **Flowability:** Poor flow requires specialized equipment.
- **Accuracy:** Precise dosing prevents variability.
- **Contamination:** Stainless steel or single-use systems reduce risks.
- **Loss:** Optimized transfer systems minimize waste.

Common Systems:

- Vacuum loading for dust-free transfer.
- Screw feeders for controlled metering.
- Drum lifters for bulk handling.

Equipment	Batch size (Kg)	Advantages	Limitations
Vaccum Loading	50-200	Dust free, automated	High initial cost
Screw Feeder	20-150	Precise metering	Limited to free – flowing materials
Drum Lifter	100-500	Handles large containers	Manual operation risks

Table 4: Material Handling Equipment Comparison

Blending and Granulation:[14,19,20,21,22]

Blending and granulation are pivotal unit operations in solid dosage form production, directly impacting content uniformity and compressibility.

Blending:

- **Objective:** Achieve uniform distribution of API and excipients.
- **Challenges:** Segregation due to differences in particle size, shape, or density.
- **Equipment:** V-blenders, bin blenders, or high-shear mixers. Scale-up may alter mixing dynamics, requiring optimization of mixing time and speed.
- **Techniques:** For low-dose APIs, sandwich blending (layering API between excipients) minimizes loss to blender surfaces.

Granulation:

- **Purpose:** Improve flow, compressibility, and uniformity by forming granules.
- **Methods:**

Wet Granulation: Uses a binder solution and high-shear mixers or planetary mixers (7–10 HP motors for 100–200 kg batches).

Dry Granulation: Employs slugging (15-ton tablet press) or roller compaction (up to 10 tons per linear inch).

Scale-Up Considerations: Granulation feed rate, binder addition rate, and drying conditions must be optimized to prevent over-granulation or poor flow.

Process Optimization:

- Monitor blend uniformity using in-process sampling and analytical testing.
- Adjust granulation parameters (e.g., impeller speed, binder concentration) based on pilot-scale trials.
- Ensure granules are free of lumps through screening or milling.
- Proper blending and granulation ensure consistent drug distribution and robust tablet properties during scale-up.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494



Figure No. 04:Wet Granulation



Figure No. 05: Dry Granulation

Drying and Particle Size Reduction:[8,12,20,22,23]
Drying and particle size reduction are essential to prepare granules for compression or encapsulation, influencing tablet quality and stability.

Drying:

- **Objective:** Remove moisture from granules to achieve uniform moisture content.
- **Equipment:** Tray dryers (lab scale) or fluid bed dryers (pilot/production scale).

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

- **Scale-Up Challenges:** Larger batches require longer drying times or higher temperatures, which may affect granule properties.
- **Parameters:** Optimize inlet temperature, airflow rate, and drying time to prevent over-drying or case hardening.

Particle Size Reduction:

- **Purpose:** Achieve desired particle size distribution for flowability, compressibility, and uniformity.
- **Equipment:** Oscillating granulators, hammer mills, or mechanical sieving devices.
- **Considerations:** Particle size impacts tablet weight, hardness, and dissolution. Excessive fines may cause flow issues.
- **Best Practices:** Use stacked sieves to analyze particle size distribution and adjust milling conditions accordingly.

Validation:

1.Conduct moisture content testing to ensure consistency.
2.Monitor particle size distribution to confirm reproducibility.
3.Document drying and milling parameters for technology transfer.
4.Optimized drying and particle size reduction enhance process reliability and product quality during scale-up.

Compression and Encapsulation:[5,9,20,23]

Compression (for tablets) and encapsulation (for capsules) are critical steps where formulation and process parameters directly affect product performance.

4.7.1 Compression:

- **Objective:** Form tablets with consistent weight, hardness, and dissolution properties.
- **Equipment:** Tablet presses designed for pilot-scale batches (e.g., 4–15 tons pressure).
- **Challenges:**Sticking/Capping: Due to improper lubrication or granule properties.
- **Weight Variation:** Caused by poor die fill or flow issues.
- **Scale-Up Strategies:**

1.Conduct prolonged trial runs at production press speeds to identify issues.
2.Optimize compression force, dwell time, and feeder settings.
3.Use force-monitoring systems to ensure uniformity.

4.7.2 Encapsulation:

- **Objective:** Fill capsules with powders or granules at precise doses.
- **Equipment:** Semi-automatic or automatic capsule fillers.
- **Considerations:** Powder flow and density are critical for consistent fill weight. Roller compaction may be needed for low-density materials.
- **Best Practices:** Validate fill weight and content uniformity through in-process controls.

Quality Control:[14,22,25]

1.Test tablets for hardness, friability, dissolution, and assay.
2.Monitor capsule weight and disintegration properties.
3.Document process parameters for batch records.
4.Robust compression and encapsulation processes ensure product quality and compliance with specifications.

Parameter	Range	Quality Impact	Monitoring Method
Compression Force	5-20kN	Hardness, Friability	Force sensors
Dwell Time	10-50 ms	Tablet integrity	Press speed adjustment
Feeder Speed	10-50 rpm	Weight uniformity	In-process weight check
Lubricant level	0.5-2% w/w	Prevents sticking	Assay testing

Table No.5: Compression Parameters and Quality Attributes

Coating and Packaging:[26,27,28,29]

Coating and packaging are optional steps for solid dosage forms but are critical for product stability, appearance, and patient compliance.

Coating:

- **Purpose:** Enhance appearance, mask taste, or control drug release.
- **Equipment:** Perforated pan coaters or fluid bed coaters.
- **Scale-Up Parameters:**

1.Spray rate, pan speed, inlet temperature, and atomization pressure.
2.Ensure uniform coating thickness to avoid variability in release profiles.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

- **Challenges:** Scaling up may alter coating uniformity or drying efficiency, requiring optimization.

Packaging:

- **Objective:** Protect the product from environmental factors (e.g., moisture, light).
- **Considerations:** Select materials (e.g., blisters, bottles) based on stability data.
- **Scale-Up Needs:** Validate packaging equipment for speed, seal integrity, and labeling accuracy.

- **Best Practices:**

1.Conduct coating trials to optimize parameters and ensure reproducibility.
2.Perform stability studies to confirm packaging suitability.
3.Document coating and packaging processes for regulatory compliance.
4.Effective coating and packaging enhance product shelf life and marketability.

Documentation and Regulatory Considerations:[30,31,32,33]

Documentation is a cornerstone of pilot scale-up, ensuring traceability, reproducibility, and compliance with GMP and regulatory standards.

Key Documents:

- **Batch Manufacturing Record (BMR):** Details raw materials, equipment, process parameters, and in-process controls.
- **Quality Control (QC) Testing Reports:** Results for hardness, friability, dissolution, and assay.
- **Stability Protocols:** Assess product shelf life under various conditions.
- **Validation Protocols:** Confirm process consistency and reproducibility.

Regulatory Considerations:[33,34,35]

- **GMP Compliance:** Pilot plants must adhere to GMP guidelines, including equipment qualification, personnel training, and environmental monitoring.
- **SUPAC Guidelines:** The FDA's Scale-Up and Post-Approval Changes (SUPAC) guidance outlines requirements for process changes during scale-up.
- **Technology Transfer:** Documented procedures ensure seamless transfer from pilot to commercial scale.

- **Best Practices:**

1.Maintain accurate and detailed records for audits.
2.Conduct risk assessments to identify critical process parameters.
3.Collaborate with regulatory teams to ensure compliance.
4.Comprehensive documentation supports regulatory approval and efficient technology transfer.

Challenges, Innovations, and Future Trends:[36,37,38,39]

Scaling up solid dosage forms presents several challenges, but advancements in technology and process understanding are driving improvements.

Common Challenges:

- **Unpredictable Scaling Effects:** Changes in equipment or batch size can alter process dynamics.
- **Equipment Variability:** Pilot-scale equipment may not fully replicate production systems.
- **Formulation Robustness:** Formulations may require reformulation to withstand large-scale processing.

Innovations:

- **Continuous Manufacturing:** Modular systems for blending, granulation, and compression improve efficiency and reduce scale-up risks.
- **Process Analytical Technology (PAT):** Real-time monitoring of critical quality attributes enhances process control.
- **Single-Use Technologies:** Disposable systems reduce contamination risks and cleaning costs.

Future Trends:

- **Bioprocessing 4.0:** Integration of data analytics and automation for predictive scale-up.
- **High-Throughput Screening:** Rapid optimization of formulations and processes.
- **Sustainability:** Energy-efficient equipment and waste reduction strategies.

- **Recommendations:**

1.Invest in flexible pilot plant designs to accommodate new technologies.
2.Leverage PAT and data analytics for real-time process optimization.
3.Foster collaboration between R&D, production, and QC teams to address scale-up challenges.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

4.By embracing innovations and addressing challenges proactively, the pharmaceutical industry can achieve efficient and reliable scale-up of solid dosage forms, ensuring high-quality products for patients.

SUPAC GUIDELINES (SCALE-UP AND POST-APPROVAL CHANGES)

The SUPAC guidelines were established by the United States Food and Drug Administration (FDA) to regulate post-approval changes in pharmaceutical manufacturing. These guidelines aim to maintain drug product quality, safety, and efficacy when modifications are made after a product has received approval. The guidelines provide a framework for managing changes systematically, including alterations in the manufacturing process, site, equipment, and batch size. SUPAC ensures that scale-up operations or post-approval changes do not compromise the final drug product[18, 19, 20].



Figure No. 06 SUPAC

Scope of SUPAC Guidelines[40,41,42,43]

SUPAC is applicable to various dosage forms, including:

1. **Immediate Release (IR) Dosage Forms**
   - Tablets and capsules that release the drug quickly after administration.
2. **Modified Release (MR) Dosage Forms**
   - Includes both sustained-release (SR) and delayed-release (DR) formulations.
3. **Semi-Solid Dosage Forms (SS)**
   - Creams, gels, and ointments used topically.
4. **Inhalation Products**
   - Metered-dose inhalers (MDIs), nasal sprays, and other inhaled drug products.

Types of Changes under SUPAC[44,45,46]

SUPAC classifies changes into three categories based on their impact on product quality:

1. Minor Changes

- Changes that pose minimal risk to product quality.
- Examples:
  - Labeling updates (non-critical information)
  - Minor adjustments in packaging material (e.g., bottle size)
- **Regulatory Action**: Reported in the **Annual Report**.

2. Moderate Changes

- Intermediate level changes that may affect the product's performance slightly.
- Examples:
  - Increase in batch size (within limits)
  - Replacement of similar equipment

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

- **Regulatory Action**: Require **Changes Being Effected (CBE)** submission.

3. Major Changes

- Significant changes that can affect the safety, efficacy, or quality of the product.
- Examples:
  - Changing the manufacturing site
  - Altering the formulation or critical manufacturing process steps
- **Regulatory Action**: Require **Prior Approval Supplement (PAS)** before implementation.

Testing Requirements for SUPAC Compliance[47,48,49,50]

To ensure consistency and quality of the modified product, the following tests are mandatory depending on the change category:

1. **Dissolution Testing**
   - Confirms that the drug release rate is consistent between the pre- and post-change product.
2. **Stability Testing**
   - Ensures the product remains stable under designated storage conditions after changes are made.
3. **Bioequivalence Studies**
   - Required for major changes that may affect drug absorption and bioavailability.
4. **Comparative Analytical Testing**
   - Compares physical and chemical characteristics of the product before and after the change.

Significance of SUPAC Guidelines[51,52,53]

1. **Consistency in Product Quality**
   - Maintains the integrity and performance of the drug across changes in manufacturing.
2. **Regulatory Compliance**
   - Aligns with FDA expectations, ensuring uninterrupted product approval status.
3. **Reduced Development Time**
   - Facilitates faster approvals for manufacturing changes with minimal documentation.
4. **Cost and Time Efficiency**
   - Prevents delays in post-approval modifications, promoting faster market response.

OVERVIEW OF PLATFORM TECHNOLOGY IN PHARMACEUTICALS

Platform technology refers to a standardized and modular approach that allows the same technological basis to be used for the development of multiple pharmaceutical products. It enables faster development, risk reduction, and scalable production by reusing established procedures and equipment[1, 15, 38].

Pharmaceutical platform technologies are designed to:

- Enhance **bioavailability**,
- Improve **drug targeting**,
- Maintain **drug stability**, and
- Support **sustained or controlled release** of medications.

Advantages of Platform Technology[53,54,55,56]

1. **Reduced Process Development Time**
   - Reduces the need for repetitive validation when launching similar products.
2. **Simplified Risk Assessment**
   - Known process parameters minimize uncertainty in formulation and scale-up.
3. **Streamlined Documentation**
   - Reduces the regulatory burden through standard templates and protocols.
4. **Consistent Product Performance**
   - Ensures batch-to-batch uniformity across various products.
5. **Efficient Technology Transfer**
   - Facilitates easy handover from R&D to manufacturing units.
6. **Minimized Training Requirements**
   - Operators can work on different products using the same core process.

Designing Platform Technologies[56,57,58]

1. **Market Identification**
   - Understand future therapeutic demands and applications that the platform can address.
2. **Defining Core Components**
   - Identify reusable modules such as base formulations, delivery mechanisms, and excipient blends.
3. **Modular Configuration**
   - Allows the platform to be adapted for different applications with minimal changes.
4. **Compatibility with Regulatory Requirements**
   - Design platforms to be flexible yet compliant with global regulatory standards.

Applications of Platform Technologies[59,60,61]

1. Medical Devices

- Reusable base systems for diagnostics and therapeutics.
- Example: A single insulin pump platform can be adapted for various insulin types.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1204-1221 www.ijprajournal.com ISSN: 2456-4494

2. Drug Delivery Systems

- Enables enhanced delivery, stability, and targeting.

a) Nanotechnology

- Drug molecules are loaded into nanoparticles for targeted therapy (e.g., cancer).
- Improves bioavailability and reduces systemic toxicity.

b) Microsphere Technology

- Biodegradable spheres allow controlled release at a specific site.
- Used for injectable and implantable drugs.

c) Liposome Technology

- Phospholipid vesicles encapsulate drugs.
- Enhances solubility and reduces drug toxicity.

d) Hot Melt Extrusion (HME)

- Produces solvent-free solid dispersions.
- Applied in the manufacture of sustained-release tablets and transdermal systems.

e) Sustained Release Formulations

- Examples include OROS (osmotic-controlled release) for once-daily dosing.
- Offers consistent plasma levels and improved patient adherence.

f) Orally Disintegrating Tablets (ODTs)

- Dissolve quickly on the tongue.
- Ideal for pediatric, geriatric, and psychiatric patients.

g) Sprinkles

- Flavored granules for pediatric dosing.
- Can be mixed with food, improving compliance.

II. CONCLUSION:

From the above finding it was concluded that the Pilot scale up techniques is one of the important tools for the optimization of large-scale production.The parameters such as Granulation feed price, compression and presence of lubricant and blending will play a important, function the development of pilot scale up techniques to big scale manufacturing solid dosage shape, With the help of pilot plant technique, we can increase our working efficiency. The significance of pilot plant scales up studies give range of relevant processing equipment's and other infrastructure facility layout.

Platform technology is revolutionizing pharmaceutical development by enhancing efficiency, reducing cost, and improving the safety and effectiveness of drug delivery systems. The integration of platform technologies with regulatory frameworks like SUPAC facilitates quicker product development cycles and seamless scale-up, ensuring both innovation and compliance.

REFERENCES:

[1]. Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. Philadelphia: Lea &Febiger; 1976. p. 681–710.

[2]. Khar RK, Ahmad FJ, Vashishtha A, Harder S, Buskirk GV, Battista JV. Pilot plant scale-up and production management. In: Khar RK, Vyas SP, Ahmad FJ, Jain GK, editors. Industrial Pharmacy. 4th ed. New Delhi: CBS Publishers & Distributors Pvt Ltd; 2013. p. 947–1002.

[3]. Bandarapalle K, et al. A comprehensive review on pilot plant scale up and platform technology. Future J Pharm Health Sci. 2024;4(1):14–25.

[4]. Chaudhari SS, Hucche B, Bawage SB. A current review on pilot plant scale-up technique. Int J Res Publ Rev. 2022;3(1):593–600.

[5]. Dhobale AV, et al. Recent advances in pilot plant scale up techniques - a review. Indo Am J Pharm Res. 2018;8(4).

[6]. Niazi SK. Handbook of pharmaceutical manufacturing formulations. Boca Raton: CRC Press; 2004. p. 121–134.

[7]. Chaudhary K, Rana AC, Bala R, Seth N. Review: scale up process of tablet production: a prospective discussion. Int J Pharm Biol Sci. 2012;2(3):223–239.

[8]. Dhobale A, Mahale AM, Shirsat M, Pethkar S, Chakote V. Recent advances in pilot plant scale up techniques - a review. Indo Am J Pharm Res. 2018;8(4):1060–1068.

[9]. Bisio A, Kabel RL. Scale-up of chemical processes: conversion from laboratory scale tests to successful commercial size. New York: Wiley; 1985. p. 48–66.

[10]. Koltunov VE. Fundamentals of scale-up techniques in pharmaceutical production. Pharm Bioprocess. 2021;8(2):34–49.

[11]. ICH Q8: Pharmaceutical Development. International Council for Harmonisation; 2009. p. 2–14.
[12]. ICH Q9: Quality Risk Management. International Council for Harmonisation; 2005. p. 5–18.
[13]. EMA. Guidelines on Process Validation. European Medicines Agency; 2014. p. 10–45.
[14]. Giri TK, Barik BB. Understanding scale-up strategies in pharmaceutical formulation. Pharm Res. 2020;37(5):456–462.
[15]. Martin A. Physical pharmacy. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 1993. p. 379–412.
[16]. Banker GS, Rhodes CT. Modern pharmaceutics. New York: Marcel Dekker; 2002. p. 115–132.
[17]. Gad SC. Pharmaceutical manufacturing handbook: production and processes. Hoboken: Wiley; 2008. p. 78–95.
[18]. Vesset DL, Hogenberg PJ. Challenges in scaling up process equipment. Process Eng. 2015;29(3):135–150.
[19]. Li J, Wang X. Scale-up challenges in novel drug delivery systems. J Pharm Sci Tech. 2022;8(4):256–268.
[20]. Misra A, Parthiban KG. Troubleshooting in scale-up: case studies. Int J Pharm Innov Res. 2018;6(2):56–65.
[21]. Basu P, Nath B. Role of process analytical technology (PAT) in scale-up. Curr Pharm Biotech. 2020;11(3):183–190.
[22]. Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 84–102.
[23]. Moyers CE, Baldwin RP. Introduction to chemical process design and economics. New York: Wiley; 1973. p. 141–157.
[24]. Sivaramakrishnan K. Analytical challenges during scale-up. Indian J Pharm Sci. 2021;83(6):922–933.
[25]. Cooke RS. The importance of fluid dynamics in scale-up. Chem Eng Des. 2017;45(3):216–227.
[26]. Marshall K, Wang Y. Computational models for scale-up processes. J Pharm Comput Model. 2019;5(1):55–68.
[27]. Tang X, Lee YM. Emerging trends in scale-up technologies. Adv Drug Deliv Rev. 2023;16(2):421–435.
[28]. Weaver PR. Regulatory considerations for pilot plant operations. Pharm Tech Today. 2020;12(7):567–578.
[29]. Pradhan S, Bose S. Innovative techniques in scale-up of biopharmaceuticals. Biotech Adv. 2019;7(1):39–54.
[30]. Prabhu S. Managing scale-up risks in continuous manufacturing. Pharm MfgInnov. 2021;4(5):189–202.
[31]. Allen LV, Popovich NG. Ansel's pharmaceutical dosage forms and drug delivery systems. 11th ed. Baltimore: Lippincott Williams & Wilkins; 2020. p. 231–250.
[32]. Chakrabarty M. Scale-up issues in high shear granulation. Drug Dev Ind Pharm. 2021;47(8):1356–1364.
[33]. Martin M, Rubinstein MH. Process validation in pharmaceutical production. Eur J Pharm Biopharm. 2020;45(4):378–386.
[34]. Aulton ME. Pharmaceutics: the design and manufacture of medicines. 5th ed. Edinburgh: Churchill Livingstone; 2017. p. 689–722.
[35]. Warrier P, Gupta K. Best practices in solid dosage scale-up. Int J Pharm Innov Tech. 2022;6(3):145–158.
[36]. Joshi V, Patel H. Overcoming barriers in pilot plant scale-up for liquid dosage forms. J Pharm Res Dev. 2019;5(1):24–36.
[37]. Remington JP, Beringer P. Remington: the science and practice of pharmacy. 22nd ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 897–918.
[38]. Sinko PJ. Martin's physical pharmacy and pharmaceutical sciences. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2010. p. 354–378.
[39]. Gilbert SB, Martin GW. Strategies for managing pilot plant scale-up. Drug Dev Ind Pharm. 2017;43(5):673–684.
[40]. Azeem S, Sharma S. Immediate release drug delivery systems: a review. Int J BiopharmToxicol Res. 2011;1(1):24–46.
[41]. Faurea P, York RC. Process control and scale up of pharmaceutical wet granulation process: a review. Eur J Pharm Biopharm. 2001;52:269–228.
[42]. Anderson EG, Parker GG, Tan B. Platform performance investment in the presence of network externalities. InfSyst Res. 2014;25(1):152–172.

[43]. Eisenmann T, Parker G, Van Alstyne M. Platform envelopment. StrategManag J. 2011;32(12):1270–1285.
[44]. American Pharmaceutical Association. (2020). Handbook of pharmaceutical excipients (8th ed.). Pharmaceutical Press.
[45]. Auger, J. P., & Levin, M. (2018). Scale-up challenges. Pharmaceutical Technology, 42(3), 34–40.
[46]. Aulton, M. E., & Taylor, K. M. G. (2017). Aulton's pharmaceutics (5th ed.). Elsevier.
[47]. European Medicines Agency. (2014). Guideline on process validation. https://www.ema.europa.eu/en/documents/scientific-guideline
[48]. Food and Drug Administration. (1995). SUPAC-IR: Scale-up and post-approval changes. https://www.fda.gov/regulatory-information
[49]. ICH.(2009).ICHQ8(R2):Pharmaceuticaldevelopment.https://www.ich.org/page/quality-guidelines
[50]. ICH. (2011). ICH Q9: Quality risk management. https://www.ich.org/page/quality-guidelinesLakshman, J. P., & Kowalski, J. (2019). Scale-up of tablets. Journal of
[51]. Pharmaceutical Innovation, 14(2), 123–134. https://doi.org/10.1007/s12247-018-9345-6
[52]. Levin, M. (2016). Pharmaceutical process scale-up (3rd ed.). CRC Press.
[53]. Parikh, D. M. (2015). Handbook of pharmaceutical granulation (3rd ed.). CRC Press.
[54]. Patel S.& Dahiya S. (2021). Continuous manufacturing advances. Journal of Pharmaceutical Sciences, 110(4), 1456-1465.
[55]. PIC/S. (2023). GMP guide – Annex 15: Qualification and validation. https://picscheme.org/en/publications
[56]. Qiu, Y., Zhang, G. G. Z., Liu, L., Porter, W., & Mantri, R. V. (Eds.). (2016). Developing solid oral dosage forms (2nd ed.). Academic Press.
[57]. Rantanen, J., &Khinast, J. (2015). Future of pharmaceutical manufacturing. Journal of Pharmaceutical Sciences, 104(11), 3612–3638. https://doi.org/10.1002/jps.24594
[58]. Rogers, T. L., & Wallick, D. (2019). Process analytical technology. Pharmaceutical Technology, 43(6), 28–34.
[59]. Swarbrick, J., & Boylan, J. C. (Eds.). (2013). Encyclopedia of pharmaceutical technology (3rd ed.). CRC Press.
[60]. United States Pharmacopeia. (2024). USP <905> Uniformity of dosage units. https://www.usp.org/standards.
[61]. World Health Organization. (2022). Good manufacturing practices. https://www.who.int/publications.